□ 管淼 郁佳莉 陆文燕 高校作为人才培养的主阵地，要坚定不移地走好拔尖创新人才自主培养之路，有组织地培养造就更多创 新人才和创新团队，把人才优势转化为培育和发展新质生产力的有效动能。近年来，学院着力培养支撑 新质生产力发展的新型技术人才，具体措施包括：一是全面推行"项目化、情境化"教学。学院打破以课 堂为重点、以教师为中心的传统模式，将企业真实项目、典型案例和技术难题引入课堂。例如，教师将 思必驰公司的"场景识别难题"转化为阶段性教学任务，学生在课堂上完成需求分析、方案设计，在实验 室进行算法模拟与验证，最终形成的优化算法获企业部分采纳，团队毕业生均被企业优先录用。这一过 程完整展示了"教学做一体化"的项目实施流程。二是强化实践教学与科研创新深度融合。学院注重引导 学生在导师的带领下参与科研项目，锻炼其科研创新和实践操作能力。以电子信息工程专业学生团队为 例，在导师带领下，历经文献调研、原理验证、原型试制、性能测试等多轮科研循环，最终成功研制出 新型传感器并获得多项专利。这标志着学生的能力已从技术应用提升至原始创新阶段。充分提升了学生 的科研成就感和创新自信心。三是着力构建跨学科培养体系，以提升学生创新思维 ...

Core Viewpoint - Biomanufacturing is identified as a key future industry in China's 14th Five-Year Plan, expected to create a market worth trillions in the next decade, driven by advancements in technology and policy support [2][5]. Group 1: Industry Overview - The biomanufacturing industry in China is nearing a total scale of 1 trillion yuan, with fermentation capacity accounting for over 70% of the global total [2][4]. - Shenzhen has become a hub for biomanufacturing, with 40% of newly established companies in this sector located there in the past three years, showcasing a significant industry clustering effect [4]. - The industry is supported by a comprehensive system of policy, funding, and technological advancements as outlined in the 14th Five-Year Plan [5]. Group 2: Key Enterprises - The article identifies 100 core enterprises in biomanufacturing, spanning the entire industry chain from upstream technology development to downstream commercial applications [7]. - Notable companies include: - Huada Technology, a leader in gene sequencing technology [17]. - Kaisa Biotech, which has achieved over 80% market share in the global long-chain dicarboxylic acid market [21]. - WuXi Biologics, representing China's capabilities in the global biopharmaceutical industry [27]. Group 3: Upstream Innovations - The upstream sector focuses on providing essential tools and technologies for research and production, with a shift towards domestic innovation and smart integration [16]. - Key trends include the localization of critical tools and the rise of AI-driven platform companies that enhance research efficiency [16][17]. - Over 75% of the 20 identified upstream enterprises are private, indicating a vibrant innovation landscape [16]. Group 4: Midstream Developments - The midstream sector is characterized by a dual structure of "upgraders" and "disruptors," with companies like Meihua Biotech and Chuaning Biotech leading in traditional fermentation while others like Kaisa Biotech innovate with new bioproducts [20][21]. - This segment contains the highest number of enterprises, with 40 out of the 100 identified companies, emphasizing the importance of production capacity and cost control [20]. Group 5: Downstream Applications - The downstream sector serves as a critical market for biomanufacturing, focusing on medical, consumer, and agricultural applications [25]. - Companies like Muyuan Foods exemplify the cost-saving potential of biomanufacturing in agriculture, while WuXi Biologics and Kelaiying represent the pharmaceutical sector's output capabilities [26][27]. - Future trends indicate a broadening of applications into new areas such as biobased textiles and environmental remediation [27].

Investment Rating - The investment rating for the pharmaceutical and biotechnology industry is "Positive" [2] Core Insights - The pharmaceutical sector experienced a weekly return of 7.81%, outperforming the CSI 300 index by 5.03%, ranking 6th among 31 primary sub-industry indices. The medical services sub-sector had the highest weekly increase of 12.34% [3][15] - The report highlights the impact of recent events such as Elon Musk's announcement regarding Neuralink's product mass production in 2026, Arrowhead Pharmaceuticals' promising clinical data for its siRNA therapy ARO-INHBE, and OpenAI's launch of "ChatGPT health," which have driven the sector's performance. The report suggests that while the brain-computer interface theme may be at a short-term emotional peak, AI medical applications still have room for growth [3][14] - Continuous investment in innovative drugs and related assets in the CXO and upstream life sciences sectors is recommended [3][14] Summary by Sections 1. Market Performance - The pharmaceutical sector's monthly return was 4.87%, outperforming the CSI 300 index by 1.37%, ranking 18th among 31 primary sub-industry indices. The medical services sub-sector had the highest monthly increase of 12.19% [15][20] 2. AI Medical Applications - AI applications in healthcare include AI+medical testing, AI+medical large models, AI+imaging, AI+e-commerce/precision marketing, and AI+gene sequencing, with notable companies such as KingMed Diagnostics, Dian Diagnostics, and BGI Genomics leading in these areas [4][16] 3. CXO and Upstream Life Sciences - Key global CXO leaders to watch include WuXi AppTec, WuXi Biologics, and Kelun Pharmaceutical. Domestic clinical CRO leaders include Tigermed and PPD. The report also highlights resource-based CXOs and upstream life sciences companies [5][16] 4. High-end Medical Devices - The report suggests focusing on companies involved in robotic applications, pharmaceutical equipment, and consumer medical devices, as demand is gradually recovering [5][16] 5. Innovative Drugs - Investment opportunities are identified in small nucleic acids, ADCs, and IO dual/multi-antibodies, with specific companies recommended for each category [6][16]

Core Insights - The Chinese nanosphere industry is experiencing rapid growth, with a projected market size of approximately 4.236 billion yuan in 2024, representing a year-on-year increase of 5.40% [1][7]. Industry Overview - Nanospheres are micron-sized spheres with nanoscale pore structures, characterized by high specific surface area and unique physical and chemical properties. They are widely used in drug delivery, liquid crystal displays, bi separation, medical diagnostics, and optoelectronic materials [2][4]. - The primary materials for nanospheres are classified into natural biomaterials (such as chitosan and collagen) and synthetic polymers (like PLGA and PVA) [2]. Nanosphere Classification - Nanospheres can be categorized based on preparation methods, including ion crosslinking, emulsion-solvent evaporation, and microfluidic technology, each with distinct principles, applicable materials, and performance characteristics [4]. Industry Chain - The upstream of the nanosphere industry includes raw materials such as chitosan, starch, cellulose, and various polymers. The midstream involves the production and manufacturing of nanospheres, while the downstream applications span drug delivery, bi separation, in vitro diagnostics, LCD spacers, conductive materials, and light diffusion films [5][6]. Market Size - The Chinese nanosphere industry is on a growth trajectory, with a market size expected to reach approximately 4.236 billion yuan in 2024, marking a 5.40% increase from the previous year [1][7]. Key Companies - Suzhou Nanwei Technology Co., Ltd. is recognized as the industry leader, leveraging proprietary technologies for precise control over sphere size and surface properties. In the first three quarters of 2025, the company reported revenues of 671 million yuan, a 22.01% increase year-on-year [8][9]. - Xian Lanyao Technology Co., Ltd. is a leading player in the adsorption separation materials sector, focusing on life sciences. The company reported revenues of 193 million yuan in the first three quarters of 2025, reflecting a 2.20% year-on-year growth [10]. Industry Development Trends 1. **Technological Innovation**: The preparation technology for nanospheres is advancing towards ultra-high precision, functional integration, and green transformation, with a focus on AI-assisted design and biodegradable materials [11]. 2. **Diverse Application Demand**: The biopharmaceutical sector remains the core growth area for nanospheres, with increasing demand in electronic displays and environmental applications, leading to a surge in market demand [12]. 3. **Domestic Substitution**: The market is transitioning from foreign monopoly to rapid growth of local enterprises, with domestic leaders like Nanwei Technology gaining market share due to competitive pricing and technological advantages [12].

证券日报网讯1月9日，纳微科技在互动平台回答投资者提问时表示，公司目前专注于生物制药分离纯化 及色谱分析检测主营业务，没有布局拉曼检测技术领域。 ...

Summary of Conference Call Records Industry Overview - The life sciences service sector, particularly the CXO segment, continues to experience high growth and is expected to deliver strong performance in 2026, benefiting from the upward cycle in innovative drugs and improved investment conditions [1][2][3] Key Companies and Performance - Notable companies in the life sciences service industry include: - **Hao Yuan Medicine**: Q3 revenue growth close to 30%, with a non-recurring profit growth of 70%. The company has secured orders exceeding 630 million yuan, a 50% year-on-year increase [2][8] - **Bai Ao Sai Tu**: Achieved a revenue growth of 60% in Q3 and recorded its first annual profit, with significant potential in humanized mouse sales and antibody business [2][8] - **WuXi AppTec**: Expected to see over 60% revenue growth in the ADC sector in the first half of 2026, with a strong order backlog [10][19] - **Kailai Ying**: Positioned well in the ADC market, with significant growth potential [10][19] - **Yangguang Nuohe**: Anticipated to achieve a profit of 300 million yuan in 2026, with a promising drug pipeline [20] Financial Performance - In the first three quarters of 2025, 16 representative life sciences service companies reported revenue and profit growth rates of high single digits and double digits, respectively. In Q3 alone, revenue and profit growth rates were double digits and 50%, indicating significant operational improvement [4][6] - The gross profit margin is expected to improve due to a clearer competitive landscape, leading to enhanced industry profitability [4] Market Trends - The overseas market is benefiting from improved investment conditions and the Federal Reserve's interest rate cuts, leading to an increase in the share of overseas business and expanding global market potential [7] - The domestic CRO market is experiencing a price recovery trend after years of intense competition, with expectations for more significant price improvements by 2027 as supply conditions stabilize [11][12] Growth Opportunities - The ADC and small nucleic acid sectors are projected to bring substantial order increases in 2026, with companies like WuXi AppTec and Hao Yuan Medicine expected to lead this growth [10][19] - The CRO sector is seeing a shift towards innovation, with companies like Yangguang Nuohe and Chengdu Xian Dao making progress in developing innovative drugs [13] Investment Recommendations - Recommended companies for investment include: - **WuXi AppTec**: Strong growth in peptide business and expected to achieve significant revenue increases [14][17] - **Kailai Ying**: Leading in peptide capacity expansion [14] - **Tigermed**: Positioned well in the CRO market with growth potential [21] - **Norseg and Prasis**: Expected to benefit from overall industry trends [17] Conclusion - The life sciences service industry is poised for continued growth, driven by innovative drug development, improved investment conditions, and a recovering market landscape. Key players are expected to deliver strong financial performance, making them attractive investment opportunities.

Core Viewpoint - The article discusses the performance of the Zhongzheng 1000 ETF Enhanced (561280), highlighting its opening price and the performance of its major holdings since its inception on August 31, 2023, which has yielded a return of 57.53% [1]. Group 1: ETF Performance - The Zhongzheng 1000 ETF Enhanced (561280) opened at 1.578 yuan, experiencing a decline of 0.19% [1]. - Since its establishment on August 31, 2023, the fund has achieved a return of 57.53% [1]. - The fund's performance over the past month has been a return of 6.26% [1]. Group 2: Major Holdings - Major stocks in the fund include: - Boqian New Materials, which opened with an increase of 0.68% [1]. - Haoyuan Pharmaceutical, which rose by 0.78% [1]. - Yingjixin, which increased by 0.56% [1]. - Caixun Co., which saw a slight increase of 0.08% [1]. - Jinma Leisure, which rose by 0.41% [1]. - Panjiang Co., which remained unchanged [1]. - Jindawei, which decreased by 0.10% [1]. - Yiyuan Communication, which increased by 0.43% [1]. - Minxin Co., which remained unchanged [1]. - Nami Technology, which rose by 0.34% [1]. [1]

2019年7月22日，苏州企业华兴源创作为"科创板第一股"闪亮登场，与另外两家苏州企业共同完成科创 板"首秀"；2025年12月30日，苏州企业强一股份成功登陆科创板，成为科创板第600家上市公司，为资 本市场再添"苏州力量"。 历时六年多深耕，苏州科创板上市公司已达58家，占全国科创板总数9.6%，位列全国第三；IPO融资总 金额超720亿元，总市值约6700亿元，位居全国第四，形成了"数量领跑、质量过硬、生态完备"的资本 市场发展格局，成为苏州经济转型升级的重要引擎。 "科创军团"提质扩容 作为全国科创企业集聚高地，苏州打造的"科创军团"可谓"兵强马壮"。 从行业分布来看，58家科创板上市公司中，新一代信息技术产业达到29家，占据半壁江山；高端装备制 造、生物医药、新材料产业各有9家、8家、8家，新能源产业3家，节能环保产业1家，全面覆盖科创板 重点支持领域。 在关键核心技术领域，苏州企业不断实现"从0到1"的突破："科创板第一股"华兴源创打破半导体检测领 域国际垄断，更以产业资本入局磁悬浮工业传输领域，开启战略延伸；阿特斯依托大型储能先发优势， 前三季度储能产品出货量达5.8GWh，同比增长32%，在海 ...

北京商报讯（记者 马换换 王蔓蕾）12月30日，伴随着强一股份（688809）上市，科创板上市公司数量 达到600家。 经统计，2025年科创板新股发行数量达19只，其中沐曦股份首日涨幅最高，达692.95%。 从600只科创板个股上市首日表现来看，纳微科技表现最好，公司于2021年6月23日登陆科创板，首日收 涨1273.98%，也系唯一一只首日涨超1000%的个股。首日表现排名第二、第三的分别是国盾量子、科德 数控，涨幅分别为923.91%、853.04%。 交易行情显示，强一股份上市首日大幅高开212.14%，开盘后保持高位震荡态势。截至当日收盘，公司 股价收涨165.61%，收于226.01元/股，总市值292.8亿元。 另外，经计算，600只科创板个股上市首日平均涨幅为129.08%。 ...

Group 1: Market Overview - The industrial bond market has seen a total issuance of 7,440 bonds, amounting to 8.60 trillion yuan, covering 29 primary industries, with 16 industries exceeding 100 billion yuan in issuance for the year, notably including public utilities, non-bank financials, and transportation [1] - The A-share market has continued to experience a volatile upward trend, with significant increases in weekly financing and a net inflow of 36.34 billion yuan into stock ETFs, indicating a positive funding environment [2] Group 2: Real Estate Sector - As of December 28, 2025, new home transactions in 20 cities totaled 774,000 units, reflecting a decrease of 16.5%, with notable declines in Beijing (21%), Shanghai (5%), and Shenzhen (38%) [3] - The secondary housing market in 10 cities recorded 756,000 transactions, a slight decrease of 0.7%, with Beijing showing a minor decline of 1% and Shanghai experiencing a 6% increase [3] Group 3: Pharmaceutical Industry - The oral semaglutide for weight loss received FDA approval, with significant clinical data from related companies indicating a shift from research validation to commercial confirmation, suggesting investment opportunities in leading firms like Goliath Pharmaceuticals and Hengrui Medicine [4] Group 4: Metals and Materials Sector - Lithium prices have reached approximately 112,000 yuan per ton, with recommendations to focus on companies with cost advantages and resource expansion potential, such as Salt Lake Co. and Tianqi Lithium [5] - Cobalt prices have increased across multiple varieties, with a recommendation to monitor Huayou Cobalt [5] - Prices for praseodymium and neodymium oxides are at a 19-month high, indicating potential investment opportunities in companies like Northern Rare Earth and Shenghe Resources [5]